Alliance Pharma PLC Total Voting Rights (4871A)
June 01 2021 - 11:00AM
UK Regulatory
TIDMAPH
RNS Number : 4871A
Alliance Pharma PLC
01 June 2021
For immediate release 1 June 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Total Voting Rights
Alliance Pharma plc (AIM: APH), the international healthcare
group, makes the following notification in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1.
As at 28 May 2021 the Company's issued share capital consists of
534,827,034 Ordinary Shares of 1p each.
The total number of voting rights in the Company is 534,827,034
and this figure may be used by shareholders as the denominator for
the calculations by which they should determine if they are
required to notify their interest in, or change to their interest
in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Oliver Steele
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with subsidiaries in Europe, the Far
East and the US and wide international reach through an extensive
network of distributors, generating sales in more than 100
countries.
We hold the marketing rights to around 80 Consumer Healthcare
brands and Prescription Medicines, which are managed on a portfolio
basis according to their growth potential. Promotional investment
is focused primarily on our Consumer healthcare brands, many of
which have significant international or multi-territory reach. Our
Prescription Medicines are generally sold in a more limited number
of local markets, and most require little or no promotional
investment.
Our strategy allows us to deliver good organic growth and to
enhance our growth rate through carefully selected
acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREASKFESNFEFA
(END) Dow Jones Newswires
June 01, 2021 12:00 ET (16:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024